Financial Statements for the second quarter of
2022 approved by the board of directors
Date of events
2022/08/04
To which item it meets
paragraph 31
Statement
1.Date of the board of directors submitted or approved:2022/08/04
2.Date of the audit committee approved:2022/08/04
3.Start and end dates of financial reports or unaudited financial
information of the reporting period(XXXX/XX/XX~XXXX/XX/XX):
2022/01/01 ~ 2022/06/30
4.Operating revenue accumulated from 1/1 to end of the period
(thousand NTD):106,810
5.Gross profit (loss) from operations accumulated from 1/1 to end of
the period (thousand NTD):48,815
6.Net operating income (loss) accumulated from 1/1 to end of the period
(thousand NTD):22,137
7.Profit (loss) before tax accumulated from 1/1 to end of the period
(thousand NTD):22,691
8.Profit (loss) accumulated from 1/1 to end of the period
(thousand NTD):17,953
9.Profit (loss) during the period attributable to owners of parent
accumulated from 1/1 to end of the period (thousand NTD):17,953
10.Basic earnings (loss) per share accumulated from 1/1 to end of
the period (NTD):0.70
11.Total assets end of the period (thousand NTD):582,654
12.Total liabilities end of the period
(thousand NTD):145,877
13.Equity attributable to owners of parent end of the
period (thousand NTD):436,777
14.Any other matters that need to be specified:None
Attachments
Original Link
Original Document
Permalink
Disclaimer
BioLASCO Taiwan Co. Ltd. published this content on 04 August 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 04 August 2022 09:46:04 UTC.
BioLASCO Taiwan Co., Ltd. is a Taiwan-based company mainly engaged in the production of Specific Pathogen Free (SPF) laboratory animals and the high-value special-mode experimental animals, as well as the introduction and production of highly-applicable disease-mode animals. The company also provides equipment related to feeding, supplies and testing platform, life science research and pharmaceutical development services.